Tumour regression

Tumour regression can occur (1) sporadically, or (2) as a consequence of treatment (treatment response).

Sporadic tumour regression

Well-known:

May occur in:

Basal cell carcinoma.^[2]

Note:

Melanocytic lesions in general, not only melanoma, may regress.^[2]^[3]

Microscopic

Features:

+/-Fibrosis.
+/-Mucin.
+/-Inflammation.
+/-Histiocytes.

Note:

There are specific criteria for malignant melanoma.

Grading of tumour regression

Colorectal carcinoma

Main article: Colorectal carcinoma

There is a three tiered regression grading system by Ryan et al. for colorectal cancer.^[4]

Esophageal carcinoma

The three tier system from Ryan et al. for colorectal cancer has been applied to esophageal carcinomas.^[5]

Ovarian carcinoma

Main article: Ovarian carcinoma

This has been examined by McCluggage et al.^[6]

References

↑ Balzer, BL.; Ulbright, TM. (Jul 2006). "Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.". Am J Surg Pathol 30 (7): 858-65. doi:10.1097/01.pas.0000209831.24230.56. PMID 16819328.
↑ ^2.0 ^2.1 Busam, Klaus J. (2009). Dermatopathology: A Volume in the Foundations in Diagnostic Pathology Series (1st ed.). Saunders. pp. 476. ISBN 978-0443066542.
↑ Speeckaert, R.; van Geel, N.; Vermaelen, KV.; Lambert, J.; Van Gele, M.; Speeckaert, MM.; Brochez, L. (Apr 2011). "Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.". Pigment Cell Melanoma Res 24 (2): 334-44. doi:10.1111/j.1755-148X.2010.00799.x. PMID 21029398.
↑ Ryan, R.; Gibbons, D.; Hyland, JM.; Treanor, D.; White, A.; Mulcahy, HE.; O'Donoghue, DP.; Moriarty, M. et al. (Aug 2005). "Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.". Histopathology 47 (2): 141-6. doi:10.1111/j.1365-2559.2005.02176.x. PMID 16045774.
↑ Takeda FR, Tustumi F, de Almeida Obregon C, Yogolare GG, Navarro YP, Segatelli V, Sallum RAA, Junior UR, Cecconello I (April 2020). "Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus". Ann Surg Oncol 27 (4): 1241–1247. doi:10.1245/s10434-019-07967-8. PMID 31664618.
↑ McCluggage, WG.; Lyness, RW.; Atkinson, RJ.; Dobbs, SP.; Harley, I.; McClelland, HR.; Price, JH. (Jan 2002). "Morphological effects of chemotherapy on ovarian carcinoma.". J Clin Pathol 55 (1): 27-31. PMID 11825920.

[pmid16819328-1] Balzer, BL.; Ulbright, TM. (Jul 2006). "Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.". Am J Surg Pathol 30 (7): 858-65. doi:10.1097/01.pas.0000209831.24230.56. PMID 16819328.

[Ref_Derm476-2] 2.0 ^2.1 Busam, Klaus J. (2009). Dermatopathology: A Volume in the Foundations in Diagnostic Pathology Series (1st ed.). Saunders. pp. 476. ISBN 978-0443066542.

[pmid21029398-3] Speeckaert, R.; van Geel, N.; Vermaelen, KV.; Lambert, J.; Van Gele, M.; Speeckaert, MM.; Brochez, L. (Apr 2011). "Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.". Pigment Cell Melanoma Res 24 (2): 334-44. doi:10.1111/j.1755-148X.2010.00799.x. PMID 21029398.

[pmid16045774-4] Ryan, R.; Gibbons, D.; Hyland, JM.; Treanor, D.; White, A.; Mulcahy, HE.; O'Donoghue, DP.; Moriarty, M. et al. (Aug 2005). "Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.". Histopathology 47 (2): 141-6. doi:10.1111/j.1365-2559.2005.02176.x. PMID 16045774.

[5] Takeda FR, Tustumi F, de Almeida Obregon C, Yogolare GG, Navarro YP, Segatelli V, Sallum RAA, Junior UR, Cecconello I (April 2020). "Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus". Ann Surg Oncol 27 (4): 1241–1247. doi:10.1245/s10434-019-07967-8. PMID 31664618.

[pmid11825920-6] McCluggage, WG.; Lyness, RW.; Atkinson, RJ.; Dobbs, SP.; Harley, I.; McClelland, HR.; Price, JH. (Jan 2002). "Morphological effects of chemotherapy on ovarian carcinoma.". J Clin Pathol 55 (1): 27-31. PMID 11825920.

[1]

[2]

[3]

[4]

[5]

[6]